^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CC-1

    i
    Other names: CC-1, Bispecific PSMAxCD3 Antibody CC-1
    Associations

    News

    Trials
    Company:
    University Hospital Tuebingen
    Drug class:
    CD3 agonist, PSMA inhibitor
    Related drugs:
    Associations

    News

    Trials
    6ms
    ProSperACC-1: Antibody CC-1 in Men With Biochemical Recurrence of Prostate Cancer (clinicaltrials.gov)
    P1, N=56, Recruiting, University Hospital Tuebingen | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    CC-1
    12ms
    the Bispecific PSMAxCD3 Antibody CC-1 in Patients With Castration Resistant Prostate Carcinoma (clinicaltrials.gov)
    P1, N=86, Recruiting, University Hospital Tuebingen | Trial completion date: Aug 2023 --> Dec 2024 | Trial primary completion date: Mar 2023 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    CC-1
    over1year
    Bispecific PSMAxCD3 Antibody CC-1 in Patients With Squamous Cell Carcinoma of the Lung (clinicaltrials.gov)
    P1/2, N=3, Terminated, German Cancer Research Center | N=86 --> 3 | Trial completion date: Sep 2025 --> May 2023 | Recruiting --> Terminated | Trial primary completion date: Mar 2025 --> May 2023; premature termination of the trial due to bad recruitment
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Checkpoint inhibition • Checkpoint block
    |
    FOLH1 (Folate hydrolase 1) • IL6R (Interleukin 6 receptor)
    |
    FOLH1 expression
    |
    CC-1
    2years
    the Bispecific PSMAxCD3 Antibody CC-1 in Patients With Castration Resistant Prostate Carcinoma (clinicaltrials.gov)
    P1, N=86, Recruiting, University Hospital Tuebingen | Trial completion date: Sep 2022 --> Aug 2023 | Trial primary completion date: Mar 2022 --> Mar 2023
    Trial completion date • Trial primary completion date
    |
    IL6 (Interleukin 6) • IL2 (Interleukin 2)
    |
    FOLH1 expression
    |
    CC-1
    almost3years
    Bispecific PSMAxCD3 Antibody CC-1 in Patients With Squamous Cell Carcinoma of the Lung (clinicaltrials.gov)
    P1/2, N=86, Recruiting, German Cancer Research Center | Not yet recruiting --> Recruiting
    Enrollment open • Checkpoint inhibition
    |
    FOLH1 (Folate hydrolase 1) • IL6R (Interleukin 6 receptor)
    |
    FOLH1 expression
    |
    CC-1
    almost3years
    Bispecific PSMAxCD3 Antibody CC-1 in Patients With Squamous Cell Carcinoma of the Lung (clinicaltrials.gov)
    P1/2, N=86, Not yet recruiting, German Cancer Research Center | Trial completion date: Jan 2025 --> Sep 2025 | Trial primary completion date: May 2023 --> Mar 2025
    Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    FOLH1 (Folate hydrolase 1) • IL6R (Interleukin 6 receptor)
    |
    FOLH1 expression
    |
    CC-1
    over3years
    Bispecific PSMAxCD3 Antibody CC-1 in Patients With Squamous Cell Carcinoma of the Lung (clinicaltrials.gov)
    P1/2, N=86, Not yet recruiting, German Cancer Research Center | Trial completion date: May 2024 --> Jan 2025 | Initiation date: Sep 2020 --> May 2021 | Trial primary completion date: Sep 2023 --> May 2023
    Clinical • Trial completion date • Trial initiation date • Trial primary completion date
    |
    FOLH1 (Folate hydrolase 1) • IL6R (Interleukin 6 receptor)
    |
    FOLH1 expression
    |
    CC-1